Not forgetting Kynamro, Sanofi's report released
http://en.sanofi.com/Images/36956_20140730_q2results_en.pdf
Kynamro as far as I can see does not get a mention. However in the Genzyme section Lemtrada for MS gets a half year total of $11M. Has Genzyme given up on Kynamro?
I'll say it once again, ISIS needs validation of its platform and what better to give it to them, ANP's 1103 and 1102.
Forget Kynamro, page-7
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
